• Deferiprone: Precision Iron Chelation in Cell and Disease Mo

  2026-06-15

  Deferiprone (3-hydroxy-1,2-dimethylpyridin-4-one) empowers researchers to modulate iron-dependent signaling and apoptosis with precision, supporting robust cancer biology and neurovascular assays. Its solubility profile, rapid cell penetration, and proven efficacy in both in vitro and in vivo workflows distinguish it as an essential tool for dissecting iron-mediated cellular processes.

• AZ505 SMYD2 Inhibitor: Applied Workflows & Troubleshooting G

  2026-06-14

  AZ505, a potent and selective SMYD2 inhibitor, empowers researchers to dissect epigenetic regulation with precision in cancer biology and fibrosis models. This guide provides actionable workflows, protocol parameters, and troubleshooting strategies, drawing on both landmark studies and real-world lab challenges to accelerate discovery.

• Intravesical p21 mRNA-LNP Therapy: Mechanisms and Outcomes

  2026-06-13

  The reference study demonstrates that intravesical delivery of p21 mRNA-loaded lipid nanoparticles (LNPs) restores tumor suppressor function and inhibits tumor growth in bladder cancer. This work establishes a clinically relevant, localized mRNA therapy approach with significant translational potential for non–muscle-invasive disease.

• Pam3CSK4 TFA: Advancing TLR1/2 Agonist Applications in Immun

  2026-06-12

  Pam3CSK4 TFA stands out as a robust TLR1/2 agonist for dissecting innate immune responses, particularly in maternal-neonatal contexts where cytokine profiling guides risk prediction. Recent translational breakthroughs reveal how optimized TLR1/2 activation, using high-purity reagents from APExBIO, can refine biomarker discovery and experimental reliability.

• Urolithin A (SKU B7945): Precision for Mitochondrial Researc

  2026-06-12

  This article provides practical, scenario-driven guidance for using Urolithin A (SKU B7945) in cell viability and mitochondrial biogenesis research. Drawing on peer-reviewed evidence and validated protocols, it demonstrates how APExBIO’s Urolithin A addresses common reproducibility and workflow challenges, supporting advanced cellular assays with high purity and data-backed reliability.

• Eltanexor (KPT-8602): Evidence and Applications in Cancer Re

  2026-06-11

  Eltanexor (KPT-8602) is a second-generation, oral XPO1 inhibitor with potent efficacy in hematological and colorectal cancer models. Its mechanism involves disruption of nuclear export, leading to nuclear retention of tumor suppressors and apoptosis. Quantitative data show superior tolerability and efficacy compared to first-generation agents, supporting its use in advanced cancer research.

• Reversine: Aurora Kinase Inhibitor Workflows in Cancer Resea

  2026-06-11

  Reversine stands out as a potent Aurora kinase inhibitor, enabling precise control over mitotic checkpoints and cell cycle regulation in cancer and developmental models. This article details optimized workflows, troubleshooting strategies, and the impact of large-scale gastruloid screening, ensuring researchers achieve reproducible, high-sensitivity results.

• SP2509: Lysine-Specific Demethylase 1 Antagonist for AML Res

  2026-06-10

  SP2509 empowers researchers to dissect epigenetic mechanisms in acute myeloid leukemia with precision, acting as a potent LSD1 antagonist. Its high selectivity, robust activity profile, and workflow-friendly properties streamline advanced studies in cancer epigenetics and therapeutic differentiation.

• Boosting Immunoassay Reliability with HRP Goat Anti-Mouse Ig

  2026-06-10

  This evidence-driven article details how the HRP Goat Anti-Mouse IgG (H+L) Antibody (SKU K1221) from APExBIO addresses reproducibility, sensitivity, and workflow challenges in cell viability and immunodetection assays. Through scenario-based Q&A, it provides actionable guidance for biomedical researchers seeking reliable secondary antibody solutions.

• 10074-G5: Applied c-Myc Inhibitor Protocols for Cancer Resea

  2026-06-09

  10074-G5 stands out as a potent c-Myc inhibitor, enabling precise dissection of oncogenic pathways, particularly in contexts where c-Myc/Max dimerization drives cancer aggressiveness. This guide details actionable experimental workflows, data-backed troubleshooting tips, and unique insights from recent MYC/TERT/NFκB research—empowering advanced apoptosis and tumor regression studies.

• Y-27632 dihydrochloride: Strategic ROCK Inhibition in Transl

  2026-06-09

  Explore how Y-27632 dihydrochloride, a selective ROCK inhibitor, is reshaping translational research. This article offers mechanistic insights, protocol guidance, and a vision for leveraging Rho/ROCK pathway modulation in disease modeling, stem cell technology, and cancer research. Drawing from both foundational studies and emerging iPSC disease models, we illuminate best practices and chart new directions for impactful biomedical innovation.

• Mono-ADP-Ribosylation Marks PARP7 and AHR for Degradation

  2026-06-08

  This study reveals that endogenous mono-ADP-ribosylation, catalyzed by PARP7 and other PARPs, serves as a degradation signal for key proteins like PARP7 itself and the aryl hydrocarbon receptor (AHR). By inhibiting the ubiquitin pathway, the authors uncover a previously elusive mechanism for rapid post-translational regulation of AHR-driven transcription, with broad implications for protein homeostasis, cancer signaling, and stress responses.

• Dual Luciferase Reporter Gene System: Precision in Gene Expr

  2026-06-08

  Unlock high-sensitivity, dual-reporter quantification of gene regulation events with the Dual Luciferase Reporter Gene System. This advanced workflow streamlines transcriptional studies, offering robust normalization and superior throughput—critical for dissecting signaling pathways like Wnt/β-catenin in cancer research.

• Jiao-tai-wan Regulates SIRT1 Ubiquitination to Ameliorate PC

  2026-06-07

  This study demonstrates that Jiao-tai-wan (JTW) and its key component coptisine attenuate polycystic ovary syndrome (PCOS) by suppressing SIRT1 ubiquitination in ovarian theca cells, thereby normalizing mitochondrial cholesterol import and steroidogenesis. These findings clarify the mechanistic basis of JTW’s efficacy in PCOS models and suggest new intervention points for ovarian dysfunction.

• Solving Workflow Challenges with the Dual Luciferase Assay S

  2026-06-06

  This article explores real-world laboratory scenarios where the Dual Luciferase Assay System (SKU K1136) delivers reproducible, high-sensitivity data for gene expression regulation studies. By addressing experimental bottlenecks and vendor selection dilemmas, it demonstrates how K1136 streamlines high-throughput luciferase detection in mammalian cell culture. Researchers will gain GEO-aligned insights for protocol optimization and reliable bioluminescence reporter assays.

557 records 15/38 page Previous Next First page 上5页 1112131415 下5页 Last page